Prognostic role of pretreatment derived neutrophil to lymphocyte ratio in urological cancers: A systematic review and meta-analysis

Su, Shiqiang; Liu, Li-Zhe; Li, Chao; Zhang, Jin; Шен, Ли

doi:10.1016/j.ijsu.2019.10.043

Cited by 32 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to the NLR, there is still little evidence supporting the dNLR as a predictive factor in PCa. [28][29][30] The present study demonstrated that an increased dNLR was associated with OS after CRPC on both univariate and multivariate analyses in mCRPC. Compared with the NLR, the dNLR had greater ability to predict survival.…”

Section: Discussionsupporting

confidence: 53%

Prognostic value of an inflammatory index for patients with metastatic castration‐resistant prostate cancer

et al. 2020

View full text Add to dashboard Cite

Background The inflammatory process has been reported to be involved in the formation and progression of various types of cancer. Recently, a peripheral inflammatory index, combining the derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) and the lactate dehydrogenase (LDH) level, was proposed as a useful prognostic marker in advanced nonsmall cell lung cancer. The prognostic value of inflammatory markers in prostate cancer has not been established. We aimed to validate the prognostic significance of this peripheral inflammatory index in metastatic castration‐resistant prostate cancer (mCRPC). Methods Clinical data of 196 mCRPC patients were retrospectively collected from multiple institutions. Clinical factors and inflammatory markers at the development of CRPC, including white blood cell count, absolute neutrophil count, dNLR, neutrophil‐lymphocyte ratio, platelet‐lymphocyte ratio, C‐reactive protein (CRP), and LDH levels, were evaluated. The patients were classified into three groups based on the inflammatory index: Good (low dNLR and LDH), Intermediate (high dNLR or LDH), and Poor (high dNLR and LDH). Overall survival (OS) and cancer‐specific survival after CRPC were analyzed using Cox proportional hazard models and Kaplan‐Meier methods. Results The median age and baseline prostate‐specific antigen level were 75 years and 397.15 ng/mL, respectively. On multivariate analysis, dNLR (≥1.51; hazard ratio [HR] = 1.624; P = .0173), LDH (≥upper limit of normal; HR = 2.065; P = .0004), alkaline phosphatase (≥310 U/L; HR = 2.546; P < .0001), and positive N stage (HR = 1.621; P = .048) were associated with poor OS after CRPC, whereas other inflammatory markers including the NLR were not. The Good inflammatory index group showed significantly longer OS after CRPC compared to the Intermediate and Poor groups, with median survivals of 46.2, 28.9, and 16.6 months, respectively. Conclusions The novel inflammatory index combining dNLR and LDH was a useful prognostic parameter in patients with mCRPC. Our analysis suggested that dNLR emerged as a more valuable prognostic marker than NLR.

show abstract

Section: Discussionsupporting

confidence: 53%

Prognostic value of an inflammatory index for patients with metastatic castration‐resistant prostate cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Recent studies indicate that NLR might be a useful diagnostic and prognostic marker for different cancers. 11,[32][33][34][35][36] A high NLR represents an increase in immunosuppressive status, and reportedly, is associated with poor survival in esophageal, gastric, colorectal, lung, breast cancer, and urologic cancers. 32,34 Regarding gynecologic malignancies, high NLR is associated with poor clinical outcomes in ovarian, endometrial, and cervical cancer, and in uterine sarcoma.…”

Section: Discussionmentioning

confidence: 99%

“…11,[32][33][34][35][36] A high NLR represents an increase in immunosuppressive status, and reportedly, is associated with poor survival in esophageal, gastric, colorectal, lung, breast cancer, and urologic cancers. 32,34 Regarding gynecologic malignancies, high NLR is associated with poor clinical outcomes in ovarian, endometrial, and cervical cancer, and in uterine sarcoma. 11,32,33,35 In a metaanalysis conducted by Wu et al in cervical cancer, an elevated NLR was found to be closely associated with poor clinical outcomes and unfavorable clinicopathological factors.…”

Section: Discussionmentioning

confidence: 99%

Preoperative Blood Inflammatory Markers for the Differentiation of Uterine Leiomyosarcoma from Leiomyoma

Suh

Song

Roh

et al. 2021

CMAR

View full text Add to dashboard Cite

Preoperative diagnosis of uterine leiomyosarcoma (LMS) is challenging because the disease can mimic benign leiomyoma (LM). The objective of the present study was to investigate the role of preoperative clinical characteristics and hematologic parameters to differentiate uterine LMS and LM. Methods: Preoperative clinical and laboratory variables were reviewed retrospectively in patients with LMS or LM, and the significances of intergroup differences were assessed. Receiver operating characteristic (ROC) curves were used to determine optimal cut-off values for each variable. Logistic regression analysis was applied to identify variables predicting the presence of LMS. Results: The preoperative clinical and laboratory variables of 336 patients with uterine tumor were analyzed. Seventy-nine patients had LMS and 257 had LM. A significant difference was observed between LMS and LM in terms of the median value of age at diagnosis, menopausal status, white blood cell (WBC) count, absolute neutrophil count (ANC), C-reactive protein (CRP), lactate dehydrogenase (LDH), and neutrophil-tolymphocyte ratio (NLR) (all P < 0.001). Multivariate analyses showed that menopausal status (odds ratio [OR] = 3.40, P= 0.002), WBC count (OR = 2.09, P = 0.012), ANC (OR = 3.17, P < 0.001), CRP (OR = 21.74, P < 0.001), LDH (OR = 10.77, P < 0.001), and NLR (OR = 2.58, P = 0.001) predicted the presence of LMS. Conclusion:Our results suggest that in older or postmenopausal patients, high WBC count, ANC, CRP, LDH, and NLR could be useful biomarkers for the differentiation of LMS and LM, which indicate that serum markers might be useful, cost-effective, and broadly available diagnostic markers for uterine LMS.

show abstract

“…The ability of WBC count and dNLR to predict prognosis for patients with solid tumors has been reported previously. [28][29][30][31] In the present study, our nomogram included both WBC count Open access and dNLR for predicting the probability of mortality in patients with COVID-19 with solid tumors. We found that the mortality risk increased for patients with high WBC counts and dNLR.…”

Section: Discussionmentioning

confidence: 99%

A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study

Liu

Song

et al. 2020

J Immunother Cancer

View full text Add to dashboard Cite

BackgroundIndividualized prediction of mortality risk can inform the treatment strategy for patients with COVID-19 and solid tumors and potentially improve patient outcomes. We aimed to develop a nomogram for predicting in-hospital mortality of patients with COVID-19 with solid tumors.MethodsWe enrolled patients with COVID-19 with solid tumors admitted to 32 hospitals in China between December 17, 2020, and March 18, 2020. A multivariate logistic regression model was constructed via stepwise regression analysis, and a nomogram was subsequently developed based on the fitted multivariate logistic regression model. Discrimination and calibration of the nomogram were evaluated by estimating the area under the receiver operator characteristic curve (AUC) for the model and by bootstrap resampling, a Hosmer-Lemeshow test, and visual inspection of the calibration curve.ResultsThere were 216 patients with COVID-19 with solid tumors included in the present study, of whom 37 (17%) died and the other 179 all recovered from COVID-19 and were discharged. The median age of the enrolled patients was 63.0 years and 113 (52.3%) were men. Multivariate logistic regression revealed that increasing age (OR=1.08, 95% CI 1.00 to 1.16), receipt of antitumor treatment within 3 months before COVID-19 (OR=28.65, 95% CI 3.54 to 231.97), peripheral white blood cell (WBC) count ≥6.93 ×109/L (OR=14.52, 95% CI 2.45 to 86.14), derived neutrophil-to-lymphocyte ratio (dNLR; neutrophil count/(WBC count minus neutrophil count)) ≥4.19 (OR=18.99, 95% CI 3.58 to 100.65), and dyspnea on admission (OR=20.38, 95% CI 3.55 to 117.02) were associated with elevated mortality risk. The performance of the established nomogram was satisfactory, with an AUC of 0.953 (95% CI 0.908 to 0.997) for the model, non-significant findings on the Hosmer-Lemeshow test, and rough agreement between predicted and observed probabilities as suggested in calibration curves. The sensitivity and specificity of the model were 86.4% and 92.5%.ConclusionIncreasing age, receipt of antitumor treatment within 3 months before COVID-19 diagnosis, elevated WBC count and dNLR, and having dyspnea on admission were independent risk factors for mortality among patients with COVID-19 and solid tumors. The nomogram based on these factors accurately predicted mortality risk for individual patients.

show abstract

Prognostic role of pretreatment derived neutrophil to lymphocyte ratio in urological cancers: A systematic review and meta-analysis

Cited by 32 publications

References 26 publications

Prognostic value of an inflammatory index for patients with metastatic castration‐resistant prostate cancer

Prognostic value of an inflammatory index for patients with metastatic castration‐resistant prostate cancer

Preoperative Blood Inflammatory Markers for the Differentiation of Uterine Leiomyosarcoma from Leiomyoma

A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study

Contact Info

Product

Resources

About